Scarica l'app Stockscreener
15.45
0.65%
-0.101
Precedente Chiudi:
$15.55
Aprire:
$15.1801
Volume 24 ore:
117
Relative Volume:
0.01
Capitalizzazione di mercato:
$43.42M
Reddito:
$5.02M
Utile/perdita netta:
$-18.31M
Rapporto P/E:
-3.4095
EPS:
-4.53
Flusso di cassa netto:
$-23.40M
1 W Prestazione:
-2.80%
1M Prestazione:
-13.03%
6M Prestazione:
+11.36%
1 anno Prestazione:
-17.98%
Intervallo 1D:
$15.18
$15.18
Intervallo di 1 settimana:
$15.17
$16.20
Portata 52W:
$12.12
$26.99
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Nome
Vtv Therapeutics Inc
Settore
Industria
Telefono
336-841-0300
Indirizzo
3980 PREMIER DR, HIGH POINT, NC
Confronta VTVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
15.18 | 43.42M | 5.02M | -18.31M | -23.40M | -4.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.47 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
511.23 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
535.70 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.68 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-05-30 | Iniziato | H.C. Wainwright | Buy |
| 2018-04-10 | Downgrade | Stifel | Buy → Hold |
| 2018-03-08 | Iniziato | ROTH Capital | Buy |
| 2018-02-08 | Iniziato | Northland Capital | Outperform |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2015-09-04 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-24 | Iniziato | Piper Jaffray | Overweight |
| 2015-08-24 | Iniziato | Stifel | Buy |
Mostra tutto
Vtv Therapeutics Inc Borsa (VTVT) Ultime notizie
vTv Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Transcript : VTv Therapeutics Inc.Special Call - MarketScreener
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewswire
vTv Therapeutics Showcases First-in-Class Type 1 Diabetes Treatment at HC Wainwright | VTVT Stock News - Stock Titan
(VTVT) Trading Signals - news.stocktradersdaily.com
(VTVT) Technical Data - news.stocktradersdaily.com
vTv resumes Phase III oral T1D drug study - The Pharma Letter
vTv Therapeutics appoints new CFO amid Phase 3 trial By Investing.com - Investing.com South Africa
vTv Therapeutics Appoints New CFO Amidst Phase 3 Trial - TipRanks
vTv Therapeutics Appoints Michael Tung, M.D., MBA, As Chief Financial Officer - citybiz
VTv Therapeutics Names Michael Tung as Finance Chief - marketscreener.com
vTv Therapeutics (VTVT) Appoints New CFO | VTVT Stock News - GuruFocus
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Fina - GuruFocus
VTv Therapeutics Names Michael Tung CFO, Effective Immediately - Nasdaq
vTv Therapeutics appoints new CFO amid Phase 3 trial - Investing.com
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief - GlobeNewswire
vTv Therapeutics Advances First-in-Class Oral Type 1 Diabetes Drug as New CFO Joins - Stock Titan
Vtv Therapeutics Inc. Appoints Michael Tung as Chief Financial Officer, Effective May 19, 2025 - MarketScreener
VTv Therapeutics: Q1 Earnings Snapshot - Bluefield Daily Telegraph
How to Take Advantage of moves in (VTVT) - news.stocktradersdaily.com
vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes - TipRanks
VTVT Advances Cadisegliatin Program with Phase 3 Study | VTVT St - GuruFocus
vTv Therapeutics advances type 1 diabetes trial By Investing.com - Investing.com South Africa
vTv Therapeutics Inc Reports Q1 2025 EPS of -$0.77, Beating Estimates; Net Loss at $5.1 Million - GuruFocus
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - The Manila Times
vTv Therapeutics Accelerates Timeline for First-Ever Oral Type 1 Diabetes Drug as Phase 3 Trial Advances - Stock Titan
VTV Therapeutics Announces Reinitiation Of Screening In CATT1 Phase 3 Trial - marketscreener.com
vTv Therapeutics advances type 1 diabetes trial - Investing.com Australia
VTv Therapeutics Resumes Cadisegliatin Testing in Type 1 Diabetes - marketscreener.com
vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treat - GuruFocus
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes | VTVT Stock New - GuruFocus
vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treatment | VTVT Stock News - GuruFocus
vTv Therapeutics Announces Reinitiation of CATT1 Phase 3 Trial for Cadisegliatin, Shortens Duration to Expedite Topline Data Expected in 2026 - Nasdaq
vTv Therapeutics Announces Reinitiation of Screening in - GlobeNewswire
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - Stock Titan
How the (VTVT) price action is used to our Advantage - news.stocktradersdaily.com
vTv Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $158,000 Holdings in vTv Therapeutics Inc. (NASDAQ:VTVT) - Defense World
vTv Therapeutics (VTVT) to Release Quarterly Earnings on Thursday - Defense World
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World
vTv Therapeutics Appoints Barry Brown as Interim CFO - MSN
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at HC Wainwright - Defense World
Q1 Earnings Forecast for VTVT Issued By HC Wainwright - Defense World
HC Wainwright Initiates vTv Therapeutics With Buy Rating, $36 Price Target - MarketScreener
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - Nasdaq
H.C. Wainwright sets $36 target for vTv Therapeutics stock By Investing.com - Investing.com Canada
Vtv Therapeutics Inc Azioni (VTVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):